IDRONOXIL

May 19th

Noxopharm receives FDA green light to progress towards Veyonda® trial

Archived

Connect with us

EXPLORE

Finfeed Portfolio

PORTFOLIOS

Next Investors

Catalyst Hunter

Wise-Owl

STOCKS

FOLLOW OUR INVESTMENT COMMENTARY & ANALYSIS

CUSTOMER NOTICE | PRIVACY POLICY | FINANCIAL SERVICES GUIDE | DISCLOSURE POLICY

The information in this website is general information only. Any advice is general advice only. Your personal objectives, financial situation or needs have not been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice. S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877).